Here, we analyzed the effects of clinically used chemotherapy in HER2-positive breast cancer on the BBB in vitro models, since patients with HER2-positive breast cancer had the highest rate of brain metastases after patients with triple-negative breast cancer, but also the best survival data (Müller et al., 2025). This evidence concerns the gene ERBB2 and breast carcinoma.